Leading law firm Blake Morgan advised private equity group, LDC, on its £18m minority investment in TMC Pharma Services.
The private equity arm of Lloyds Banking Group, LDC specialises in investing in mid-market UK headquartered businesses. It is committed to backing 100 new management teams over the next five years.
Established in 2001, TMC Pharma Services (TMC) is a global pharmaceutical development organisation that specialises in innovative treatments for rare diseases and oncology. TMC has successfully supported over 150 Orphan Drug Designations in the past 10 years; in the USA, EU, Japan and Australia. The business provides a full range of expert pharma and biotech support services, from pre-clinical to post-marketing, for human medicines and devices.
Blake Morgan’s corporate team, led by Richard Jones, enabled LDC to achieve true value on their investment, understanding the unique IP, physical assets and market growth potential of TMC Pharma Services.
Blake Morgan Corporate Partner, Richard Jones commented:
We are delighted to have been able to support LDC with this exciting investment. This is an important step for TMC Pharma Services and LDC's investment will allow its management team to continue their international expansion into the US and Asia markets. We wish the whole team at TMC every success as it moves forward into the next phase of growth.
This builds on Blake Morgan’s significant experience supporting private equity firms through their investment process, applying corporate transaction experience and strength and depth found within the commercial team working across the health, pharmaceutical and biotech sectors.
The Blake Morgan core team comprised Richard Jones, James Vaughan and Sara Trevor (corporate) supported by Hannah Waterworth and Joanne Davies (employment), Cathy Bryant (tax), Rhian Davies and Paul Duggan (banking and finance), Tomos Lewis (commercial) and Eve Piffaretti (regulatory).